If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTyratech Regulatory News (TYR)

  • There is currently no data for TYR

Pre Close Trading Update

28 Jul 2016 07:00

RNS Number : 4329F
TyraTech, Inc.
28 July 2016
 

Strictly Embargoed for 07.00 on 28 July 2016

TyraTech, Inc.

("TyraTech" or the "Company")

Pre Close Trading Update

TyraTech, Inc. (AIM: TYR and TYRU), a life sciences technology company focused on nature-derived insect and parasite control products gives the following update on trading ahead of the announcement of its half year results to 30 June 2016.

The Company's trading performance in the first half continues the upward trend from prior periods, with unit sales of the Vamousse® head lice product line continuing to progress and operating expense efficiencies now being realised. These trends are anticipated to continue throughout the second half. The Board expects the net loss over the year to remain in line with current market expectations.

Vamousse

Unit sales of Vamousse were in line with expectations, showing strong growth over the corresponding period for 2015 across all geographies and customers. Vamousse continues to establish itself as a leading brand and is performing well in the market against competitor products, gaining market share.

Revenues associated with these sales have been modestly impacted by currency translation effects on UK sales and by revenue recognition factors, due to sale or return associated with one new US customer. These impacts are expected to continue through the rest of the year.

PureScience™

The PureScience portfolio of animal health products is showing good results in field and customer trials, and three products were launched for poultry and swine production at the end of the half. 

The roll-out of PureScience in the first half was slower than anticipated mainly due to the time of completing the field trials and it is now expected that the revenue impact will be in the second half of the year.

The Company expects to announce its interim results in mid-September 2016 and will give a further update at that time.

*-ends-*

 

For further information please visit: www.tyratech.com or contact:

TyraTech Inc.

Bruno Jactel, Chief Executive Officer

Erica Boisvert, Chief Financial Officer

 

Tel: +1 919 415 4340

Tel: +1 919 415 4287

 

SPARK Advisory Partners Limited (Nominated Adviser)

Matt Davis / Mark Brady

 

 

Tel: +44 20 3368 3551

 

Allenby Capital Limited (Joint Broker)

Chris Crawford

 

 

Tel: +44 20 3328 5656

 

Whitman Howard Limited (Joint Broker)

Ranald McGregor-Smith

 

 

Tel: +44 20 7659 1250

 

Belvedere Communications (PR)

John West / Kim van Beeck

 

 

Tel: +44 20 3567 0510

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPGUAUMUPQGAM
Date   Source Headline
29th Sep 20107:00 amRNSInterim Results
9th Sep 20109:46 amRNSNotice of Interim Results
25th Aug 20104:50 pmRNSUnrestricted Trading Line Completed
5th Aug 20107:00 amRNSBoard Change
29th Jul 20102:40 pmRNSMajor Interest in Shares
19th Jul 20107:00 amRNSEstablishing Unrestricted Trading Line
9th Jul 201012:41 pmRNSResult of AGM and Board Changes
23rd Jun 20104:06 pmRNSMajor Interest in Shares
22nd Jun 20107:00 amRNSResults for the year ended 31 December 2009
21st May 20105:35 pmRNSDirectors' Disclosure
19th May 20105:15 pmRNSResult of Special Meeting
18th May 20107:00 amRNSUpdate to Fundraising
10th May 20107:00 amRNSFundraising and Trading Update
29th Apr 20107:00 amRNSProspective fundraising of approximately £1m
24th Feb 20107:00 amRNSPreliminary Results
4th Feb 20105:41 pmRNSAward of Share Options
4th Feb 20107:00 amRNSExpanded Terminix Agreement
5th Jan 20107:00 amRNSBoard Changes
24th Nov 20097:00 amRNSTrading Update
11th Nov 20097:00 amRNSDirector Share Purchase
9th Nov 20097:00 amRNSArysta Insecticide Product Launch
5th Oct 20097:00 amRNSKraft Milestone and Contract
21st Sep 20093:41 pmRNSDirector Share Purchase
16th Sep 20097:01 amRNSChange of Auditor
16th Sep 20097:01 amRNSBoard Changes
16th Sep 20097:00 amRNSInterim Results
10th Sep 20097:00 amRNSClarke Partnership
19th Aug 20097:00 amRNSStrategic Partnership Agreement
28th Jul 20097:00 amRNSNew Product Launch
23rd Jul 20097:00 amRNSTrading Update
22nd Jun 20092:03 pmRNSAnnual Report and Accounts
21st May 200912:15 pmRNSAGM Statement
20th May 20097:00 amRNSExpanded Agreement with Terminix
20th Apr 20097:00 amRNSTerminix First Shipment
16th Apr 20096:02 pmRNSDirectors Share Purchase
15th Apr 20096:20 pmRNSDIRECTORS SHARE PURCHASE
14th Apr 20095:44 pmRNSDirectors Share Purchase
9th Apr 20095:17 pmRNSDirector Share Dealings
7th Apr 20095:00 pmRNSCorrected Notice of AGM
1st Apr 20097:06 amRNSPreliminary Results
30th Mar 20097:00 amRNSNew product Launches
20th Mar 20097:00 amRNSNotice of Preliminary Results
27th Jan 20097:00 amRNSShare Buy Back Transaction
16th Jan 20097:04 amRNSOptions Award
16th Jan 20097:02 amRNSShare Buy Back
16th Jan 20097:00 amRNSSalary Reductions
14th Jan 20097:00 amRNSNew Joint Venture - TyraChem
23rd Dec 20087:00 amRNSProgress with Kraft Foods Partnership
24th Nov 20087:00 amRNSAgreement Signed with Terminix
20th Oct 20087:00 amRNSSummons from Molecular Securities, Inc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.